On August 31, MEDBOT-B fell 5.91% in regular trading, trading at HK$20.76/share, with turnover of HK$22.52 million. The decline was driven by a confluence of negative catalysts including a delayed board meeting for interim results review, key management departures, and a finance lease termination.

The company's board meeting, originally scheduled for August 27, was postponed to August 31 as management required additional time to finalize the first-half results for the six months ended June 30. The delay raised market concerns over the pace of financial data confirmation, despite the company having previously issued a positive profit alert projecting net profit of RMB 28 million to RMB 40 million, marking its first-ever half-year profit.

Compounding the uncertainty, executive director Liu Yu and non-executive director Liang Min both resigned, with the board nominating Jonathan W Chen and Hui Qing as non-executive director candidates pending an extraordinary general meeting. Separately, the company's 98%-owned subsidiary agreed to pay RMB 20.9 million to terminate a finance lease with a MicroPort affiliate, gaining ownership of 27 surgical robot prototypes while reducing future interest expenses and optimizing its debt structure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)